This article is more than 5 years old. Information may no longer be current.

Health Canada approves Vyzulta

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch + Lomb’s Vyzulta has been issued a Notice of Compliance from Health Canada for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release.

Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), a once-daily monotherapy that targets two pathways to reduce aqueous humor to lower IOP, is the first new open-angle glaucoma treatment in Canada in nearly two decades, the release said.

“With today’s approval of Vyzulta, doctors and patients with glaucoma now have a new innovative treatment option that can help provide consistent and sustained IOP reduction,” Richard Lajoie, president of Bausch Health, Canada, said in the release. “High IOP is the only modifiable risk factor that can help slow down the progression of the disease to help patients maintain healthy vision.”